ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 796

Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases

Laure Delaval1,2, Aurélie Daumas3, Maxime Samson4, Mikael Ebbo5, Hubert de Boysson6, Eric Liozon7, Henry Dupuy8, Alexis Regent9, Mathieu Puyade10, Daniel Blockmans11, Estibaliz Lazaro12, Ygal Benhamou13, Karim Sacre14, Alice Bérezné15, Loïc Guillevin2,9,16 and Benjamin Terrier17,18,19, 1National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, 2Internal medicine, Cochin University Hospital, paris, France, 3Department of Internal Medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Marseille, France, 4Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5internal medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Paris, France, 6Department of Internal Medicine, Caen University Hospital, Caen, France, 7Departement of Internal Medicine, Limoges University Hospital, Limoges, France, 8Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, 9National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 10Department of Internal Medicine, University Hospital of Poitiers, Poitiers, France, 11General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, 12Department of Internal Medecine and Clinical Immunology, Bordeaux University Hospital, Pessac, France, 13Department of internal medicine, University Hospital of Rouen, Rouen, France, 14Department of Internal Medicine, Bichat Hospital, Paris, France, 15Department of internal medicine, CHR Annecy-Genevois, Metz-Tessy, France, 16French Vasculitis Study Group (FVSG), Paris, France, 17Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 18Internal Medicine, Cochin University Hospital, Paris, France, 19French Vasculitis Study Group (FVSG), paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: giant cell arteritis, takayasu arteritis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary large-vessel vasculitis (LVV) include giant cell arteritis (GCA) and Takayasu arteritis (TA). Age at onset is commonly used to distinguish GCA and TA. TA usually occurs before 50 years, whereas GCA occurs after age 50. However, GCA onset before age 60 remains very rare, reason why LVV between age 50 and 60 could be difficult to classify.

Methods: We conducted a national, retrospective study including patients with LVV, defined by histological (temporal artery biopsy) and/or imaging (circumferential thickening and/or hypermetabolism on FDG PET/CT) evidence of inflammatory vascular disease, and aged between 50 and 60 years at onset (LVV50-60). Cases were compared to controls with GCA aged over 60 years (LVV>60), and matched on gender with a ratio of 1:1.

Results:

We included 183 patients (136 women). Initial symptoms of LVV were: constitutional symptoms in 144 (79%) cases, cephalic symptoms in 133 (73%), polymyalgia rheumatica in 55 cases (30%), peripheral limb ischemic manifestations in 42 (23%), ocular signs in 32 (17%), stroke in 4 cases (2%) and mesenteric ischemia in 2 cases (1%). Temporal artery biopsy showed evidence of vasculitis in 78 (43%) cases.

Computed tomography (CT) angiography was performed in 102 (56%) cases and was abnormal in 74%, involving aorta in 83% (thoracic 29%, abdominal 8% and both 63%), subclavian artery in 26%, iliofemoral artery in 18% and carotid artery in 14%. Isolated aortitis was observed in 38%.

FDG PET/CT scan was performed in 105 (57%) cases, showing hypermetabolism in 90%. Overall, aortitis was noted on CT angiography and/or FDG-PET/CT in 113 (78%) cases, without any cephalic symptoms in 22%.

All patients received glucocorticoids. After a median follow-up of 43.8 months, 78 (31%) patients required second-line therapy, 27 (18%) three-line, and 14 (9%) more lines. Overall, 35% received methotrexate and 12% biological agent (anti-TNFa and/or IL-6 blockade). Fifteen patients required surgery (bypass surgery or angioplasty). At the end of follow-up, only 45% had discontinued glucocorticoids.

Case-control comparison showed that LVV50-60 had more frequent peripheral limb ischemic manifestations (23 vs 5%, P<0.0001), and less frequent cephalic symptoms (72 vs 90%, P<0.0001) and ocular signs (17 vs 27%, P=0.04). CT angiography and FDG PET/CT scan were more frequently abnormal in LVV50-60 (41 vs 23%, P<0.0001; and 51 vs 27%, P=0.007, respectively), with aorta being more frequently involved (78 vs 47%, P<0.0001). LVV50-60 received a median of 2 lines of treatment compared to one in LVV>60 (P=0.0002). LVV50-60 had more frequent surgery (10 vs 0%, P<0.0001), received more frequent biological agents (12 vs 3%, P=0.003), and had at last follow-up higher median prednisone dose (8.8 vs 6.5 mg/d, P=0.048) and lower frequency of patients with prednisone <7.5 mg/d (71 vs 83%, P=0.01) compared to LVV>60.

Conclusion: Primary LVV onset between 50 and 60 years identifies a subset of patients with more frequent aorta and peripheral limb vascular involvement compared to patients with LVV onset after 60. LVV between 50 and 60 were also characterized by more refractory disease requiring more methotrexate and/or biological agent.


Disclosure: L. Delaval, None; A. Daumas, None; M. Samson, None; M. Ebbo, None; H. de Boysson, None; E. Liozon, None; H. Dupuy, None; A. Regent, None; M. Puyade, None; D. Blockmans, None; E. Lazaro, None; Y. Benhamou, None; K. Sacre, None; A. Bérezné, None; L. Guillevin, None; B. Terrier, None.

To cite this abstract in AMA style:

Delaval L, Daumas A, Samson M, Ebbo M, de Boysson H, Liozon E, Dupuy H, Regent A, Puyade M, Blockmans D, Lazaro E, Benhamou Y, Sacre K, Bérezné A, Guillevin L, Terrier B. Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/presentation-and-outcome-of-large-vessel-vasculitis-diagnosed-between-50-and-60-years-case-control-study-based-on-183-cases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/presentation-and-outcome-of-large-vessel-vasculitis-diagnosed-between-50-and-60-years-case-control-study-based-on-183-cases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology